{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.14.10-dev",
    "document_metadata": {
      "name": "Temporary Network",
      "version": "_akJ3f4e--_"
    },
    "namespace_url": {},
    "namespace_pattern": {},
    "annotation_url": {},
    "annotation_pattern": {},
    "annotation_list": {},
    "biodati_network_id": "01E9HFK1WPDF1W198Y3T86EGV8",
    "annotation_curie": [],
    "annotation_miriam": []
  },
  "nodes": [
    {
      "function": "Abundance",
      "concept": {
        "namespace": "CHEBI",
        "name": "angiotensin II"
      },
      "id": "17c2386466aa664335d7eeca2063bf1f",
      "bel": "a(CHEBI:\"angiotensin II\")"
    },
    {
      "function": "Abundance",
      "concept": {
        "namespace": "TAX",
        "name": "Severe acute respiratory syndrome coronavirus 2"
      },
      "id": "c41851da59cc36c21b2e8acf24c1f46d",
      "bel": "a(TAX:\"Severe acute respiratory syndrome coronavirus 2\")"
    },
    {
      "function": "BiologicalProcess",
      "concept": {
        "namespace": "GO",
        "name": "epidermal growth factor receptor signaling pathway"
      },
      "id": "bd8c8ef63fe64c16b5c234873e164931",
      "bel": "bp(GO:\"epidermal growth factor receptor signaling pathway\")"
    },
    {
      "function": "BiologicalProcess",
      "concept": {
        "namespace": "GO",
        "name": "pattern recognition receptor signaling pathway"
      },
      "id": "7318f23bd3ef6a3393c5bda5d247821a",
      "bel": "bp(GO:\"pattern recognition receptor signaling pathway\")"
    },
    {
      "function": "BiologicalProcess",
      "concept": {
        "namespace": "GO",
        "name": "positive regulation of interleukin-6 production"
      },
      "id": "42b95ca6d521f67bf2dacfc5aa7da5a9",
      "bel": "bp(GO:\"positive regulation of interleukin-6 production\")"
    },
    {
      "function": "BiologicalProcess",
      "concept": {
        "namespace": "GO",
        "name": "tumor necrosis factor-mediated signaling pathway"
      },
      "id": "a4c18d71b2df953793e49c1a7699c5ac",
      "bel": "bp(GO:\"tumor necrosis factor-mediated signaling pathway\")"
    },
    {
      "function": "Complex",
      "concept": {
        "namespace": "GO",
        "name": "NF-kappaB complex"
      },
      "id": "2b8e47488405cbf906efe3bac140985b",
      "bel": "complex(GO:\"NF-kappaB complex\")"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "concept": {
            "namespace": "HGNC",
            "name": "IL6"
          },
          "id": "8a1d3c4828c5416eba867c395cc65caa",
          "bel": "p(HGNC:IL6)"
        },
        {
          "function": "Protein",
          "concept": {
            "namespace": "HGNC",
            "name": "STAT3"
          },
          "id": "9523cd88bdb7daf4a0aaf38eb43fbe28",
          "bel": "p(HGNC:STAT3)"
        }
      ],
      "id": "69ed28f0beb7767cf3eff066627216c0",
      "bel": "complex(p(HGNC:IL6), p(HGNC:STAT3))"
    },
    {
      "function": "Protein",
      "concept": {
        "namespace": "HGNC",
        "name": "ACE2"
      },
      "id": "bb9a231a2c68ff8f3bad2adad9ed6a94",
      "bel": "p(HGNC:ACE2)"
    },
    {
      "function": "Protein",
      "concept": {
        "namespace": "HGNC",
        "name": "ADAM17"
      },
      "id": "8351a14adf985bc7b6e72b7fea9a3f1d",
      "bel": "p(HGNC:ADAM17)"
    },
    {
      "function": "Protein",
      "concept": {
        "namespace": "HGNC",
        "name": "AGTR1"
      },
      "id": "aaf1fa632bd4a29e5095caf17491bb89",
      "bel": "p(HGNC:AGTR1)"
    },
    {
      "function": "Protein",
      "concept": {
        "namespace": "HGNC",
        "name": "EGF"
      },
      "id": "7c6e2be826c1c81b55f7f6a99b4bab53",
      "bel": "p(HGNC:EGF)"
    },
    {
      "function": "Protein",
      "concept": {
        "namespace": "HGNC",
        "name": "IL6"
      },
      "id": "8a1d3c4828c5416eba867c395cc65caa",
      "bel": "p(HGNC:IL6)"
    },
    {
      "function": "Protein",
      "concept": {
        "namespace": "HGNC",
        "name": "IL6R"
      },
      "id": "92536fcad84ecfcda5039c198ce6946d",
      "bel": "p(HGNC:IL6R)"
    },
    {
      "function": "Protein",
      "concept": {
        "namespace": "HGNC",
        "name": "STAT3"
      },
      "id": "9523cd88bdb7daf4a0aaf38eb43fbe28",
      "bel": "p(HGNC:STAT3)"
    },
    {
      "function": "Pathology",
      "concept": {
        "namespace": "MESH",
        "name": "Severe Acute Respiratory Syndrome"
      },
      "id": "ed25a06ed1c83ba5083d0f22650e967f",
      "bel": "path(MESH:\"Severe Acute Respiratory Syndrome\")"
    }
  ],
  "links": [
    {
      "line": 13,
      "relation": "increases",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "citation": {
        "namespace": "PubMed",
        "identifier": "32325025"
      },
      "annotations": {},
      "object": {
        "modifier": "Activity"
      },
      "source": 0,
      "target": 10,
      "key": "7673afd97252be43699748ca3feb2e0b"
    },
    {
      "line": 8,
      "relation": "increases",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "citation": {
        "namespace": "PubMed",
        "identifier": "32325025"
      },
      "annotations": {},
      "source": 1,
      "target": 3,
      "key": "eebdfacdb7b9086dc79b3976a6de23b5"
    },
    {
      "line": 16,
      "relation": "increases",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "citation": {
        "namespace": "PubMed",
        "identifier": "32325025"
      },
      "annotations": {},
      "object": {
        "modifier": "Degradation"
      },
      "source": 1,
      "target": 8,
      "key": "4717cefbdb0e3d3fa012f5318e342a3b"
    },
    {
      "line": 1,
      "relation": "increases",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "citation": {
        "namespace": "PubMed",
        "identifier": "32325025"
      },
      "annotations": {},
      "object": {
        "modifier": "Activity"
      },
      "source": 2,
      "target": 6,
      "key": "385c1c99d550166c18667f0057de7dbd"
    },
    {
      "line": 7,
      "relation": "increases",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "citation": {
        "namespace": "PubMed",
        "identifier": "32325025"
      },
      "annotations": {},
      "object": {
        "modifier": "Activity"
      },
      "source": 3,
      "target": 6,
      "key": "1b31e5212eaccdd8bf5c6000fa3cf4be"
    },
    {
      "line": 5,
      "relation": "increases",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "citation": {
        "namespace": "PubMed",
        "identifier": "32325025"
      },
      "annotations": {},
      "source": 4,
      "target": 15,
      "key": "711479cbf3d6517f91f548db60d58723"
    },
    {
      "line": 0,
      "relation": "increases",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "citation": {
        "namespace": "PubMed",
        "identifier": "32325025"
      },
      "annotations": {},
      "object": {
        "modifier": "Activity"
      },
      "source": 5,
      "target": 6,
      "key": "82c40b55fd55e261a77136537c108179"
    },
    {
      "line": 6,
      "relation": "increases",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "citation": {
        "namespace": "PubMed",
        "identifier": "32325025"
      },
      "annotations": {},
      "subject": {
        "modifier": "Activity"
      },
      "source": 6,
      "target": 4,
      "key": "bcfff1e2a95b32b41a16f12c88f82bb2"
    },
    {
      "line": 9,
      "relation": "increases",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "citation": {
        "namespace": "PubMed",
        "identifier": "32325025"
      },
      "annotations": {},
      "subject": {
        "modifier": "Activity"
      },
      "source": 7,
      "target": 4,
      "key": "f4ebb243acad5ecbfd996305900a38e9"
    },
    {
      "relation": "partOf",
      "source": 12,
      "target": 7,
      "key": "36e964c22e6aec6068c12001fadfc125"
    },
    {
      "relation": "partOf",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "source": 12,
      "target": 7,
      "key": "b3951560316de570fe546784b812311c"
    },
    {
      "relation": "partOf",
      "source": 14,
      "target": 7,
      "key": "7a3a58584f31d46d824c8c420f08b787"
    },
    {
      "relation": "partOf",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "source": 14,
      "target": 7,
      "key": "d7ae8b501d6f4b86eb8001ef69c33434"
    },
    {
      "line": 14,
      "relation": "directlyDecreases",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "citation": {
        "namespace": "PubMed",
        "identifier": "32325025"
      },
      "annotations": {},
      "subject": {
        "modifier": "Activity"
      },
      "source": 8,
      "target": 0,
      "key": "b61f86c29d0d7205eaf500a988c62807"
    },
    {
      "line": 15,
      "relation": "directlyDecreases",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "citation": {
        "namespace": "PubMed",
        "identifier": "32325025"
      },
      "annotations": {},
      "subject": {
        "modifier": "Degradation"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 8,
      "target": 8,
      "key": "a0e001167b5cb04b9a00bc96dc941922"
    },
    {
      "line": 3,
      "relation": "increases",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "citation": {
        "namespace": "PubMed",
        "identifier": "32325025"
      },
      "annotations": {},
      "subject": {
        "modifier": "Activity"
      },
      "source": 9,
      "target": 5,
      "key": "9df81fa73205b855c0e90b0a22ce722f"
    },
    {
      "line": 4,
      "relation": "increases",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "citation": {
        "namespace": "PubMed",
        "identifier": "32325025"
      },
      "annotations": {},
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 9,
      "target": 11,
      "key": "3538af0d9d72288bdcbb035def3eba3f"
    },
    {
      "line": 11,
      "relation": "increases",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "citation": {
        "namespace": "PubMed",
        "identifier": "32325025"
      },
      "annotations": {},
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 9,
      "target": 13,
      "key": "478fb026f7e31097cac7a410d7318e3a"
    },
    {
      "line": 12,
      "relation": "directlyIncreases",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "citation": {
        "namespace": "PubMed",
        "identifier": "32325025"
      },
      "annotations": {},
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 10,
      "target": 9,
      "key": "69a861c037515dc8c25794ac1c20445a"
    },
    {
      "line": 2,
      "relation": "increases",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "citation": {
        "namespace": "PubMed",
        "identifier": "32325025"
      },
      "annotations": {},
      "subject": {
        "modifier": "Activity"
      },
      "source": 11,
      "target": 2,
      "key": "9ec9ec11af26f76f817b29cc661b0e38"
    },
    {
      "line": 10,
      "relation": "increases",
      "evidence": "SARS-CoV-2 uses angiotensin converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2) as cell entry receptors, followed by a cytokine-related syndrome, ARDS, which is induced by the hyper-activation of the transcription factor NF-κB, most likely in nonimmune cells including lung epithelial cells. ACE2 molecules on the cell surface are occupied by SARS-CoV-2. Angiotensin 2 (AngII) then increases in the serum due to a reduction of ACE2mediated degradation. SARS-CoV-2 itself activates NF-κB via pattern recognition receptors (PPRs), and the accumulated AngII induces inflammatory cytokines including TNFα and IL-6-soluble (s)IL-6R via disintegrin and metalloprotease 17 (ADAM17), followed by activation of the IL-6  amplifier (IL-6 AMP), which describes enhanced NF -κB activation machinery via the coactivation of NF-κB and transcription factor STAT3. The molecules underlined indicate possible therapeutic targets for COVID-19, which is a cytokine release syndrome (CRS).",
      "citation": {
        "namespace": "PubMed",
        "identifier": "32325025"
      },
      "annotations": {},
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 13,
      "target": 7,
      "key": "b19d5e7471d0dca3ed82e27e0ea0753d"
    }
  ]
}